Insight Genetics Gets New NCI Contract to Identify Resistance Mutations in Lung Cancer Patients
The National Cancer Institute has awarded Insight Genetics a $1.5 million Phase II continuation of its SBIR contract for developing a companion diagnostic to assess patient resistance to therapies for non-small cell lung cancer.
Read More